ACRF funding plays key role in search for a cure for Acute Myeloid Leukaemia
ACRF is delighted to be associated with positive research findings leading to possible treatments for Acute Myeloid Leukaemia (AML).
Scientists from the Walter and Eliza Hall Institute (WEHI) in Melbourne, in collaboration with local and international scientists, have found a potential ‘achilles heel’ for this terrible disease which has such a poor prognosis.
They have found that AML cells may be susceptible to medications that target a protein called Mcl-1. Treatments removing that protein from AML cells can rapidly kill these aggressive cancer cells.
“Importantly, non-cancerous blood cells were much less susceptible to dying when Mcl-1 was depleted,” said lead researcher, Dr Stefan Glaser.



